Which company developed ibrutinib and its product background introduction

Ibrutinib (also known as ibrutinib, English name Ibrutinib) is an oral Bruton's tyrosine kinase (BTK) inhibitor. It is a targeted therapy drug and is mainly used to treat various types of hematological malignancies, such as chronic lymphocytic leukemia ( pan>CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM), etc. Its advent has brought a huge breakthrough in the treatment of blood cancers, especially for patients who cannot tolerate chemotherapy or who are relapsed and refractory, providing a new treatment option.

Ibrutinib was originally developed by the American biotechnology company Pharmacyclics (Pharmaceut) and jointly developed with Janssen Biotech (Janssen Biotech), a subsidiary of Johnson & Johnson (Johnson & Johnson). In 2015, Pharmacyclics was acquired by AbbVie (AbbVie) for 21 billion. Since then, ibrutinib has become one of AbbVie’s important products. According to the cooperation agreement, ibrutinib is jointly owned and sold by AbbVie and Janssen, so the drug may be launched by one or both of them in different countries and regions.

Globally, the commercialization of ibrutinib is advancing rapidly. It was first approved by the US FDA in 2013 for the treatment of mantle cell lymphoma, and has since been expanded to include CLL, WM, marginal zone lymphoma and other diseases. In clinical trials, ibrutinib has shown good efficacy and tolerability, especially in the field of CLL. It can extend the progression-free survival of patients and significantly reduce the recurrence rate of the disease, making it one of the standard treatments in this field.

In China, ibrutinib has also been approved for marketing and included in the national medical insurance directory, making it one of the more accessible targeted drugs for patients with hematological tumors. The drugs are marketed and sold by Janssen China. In recent years, with the launch of more BTK inhibitors, ibrutinib's market competition has intensified. However, ibrutinib still occupies an important position in the field of hematological tumor treatment with its first-in-class advantages, rich indications and long-term real-world data accumulation.

Reference materials:https://www.imbruvica.com/